Trade Report: The Brokerages Set Shire PLC (NASDAQ:SHPG) PT at $234.43

The Brokerages Set Shire PLC (NASDAQ:SHPG) PT at $234.43

Shire PLC (NASDAQ:SHPG) has been given an average recommendation of “Buy” by the twenty-seven research firms that are presently covering the firm. Five research analysts have rated the stock with a hold recommendation and twenty-two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $234.43.

SHPG has been the subject of several recent analyst reports. Shore Capital restated a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 14th. Zacks Investment Research raised Shire PLC from a “hold” rating to a “buy” rating and set a $192.00 price target for the company in a report on Wednesday, June 29th. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a report on Tuesday, June 28th. Leerink Swann reaffirmed a “buy” rating and issued a $213.00 price target (down previously from $225.00) on shares of Shire PLC in a report on Thursday, June 16th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $230.00 price target on shares of Shire PLC in a report on Tuesday, July 12th.

Shire PLC (NASDAQ:SHPG) opened at 194.50 on Tuesday. The firm’s 50-day moving average price is $195.56 and its 200-day moving average price is $187.04. Shire PLC has a 12 month low of $147.60 and a 12 month high of $231.32. The firm has a market cap of $57.93 billion, a price-to-earnings ratio of 40.42 and a beta of 1.16.

Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the prior year, the company earned $2.63 EPS. The firm’s revenue for the quarter was up 55.9% compared to the same quarter last year. Equities research analysts predict that Shire PLC will post $12.92 earnings per share for the current year.

The business also recently declared a dividend, which was paid on Friday, October 7th. Stockholders of record on Friday, September 9th were given a $0.139 dividend. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.

Several hedge funds and other institutional investors have recently bought and sold shares of SHPG. FTB Advisors Inc. increased its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Shire PLC by 5.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,728 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 82 shares during the last quarter. Baldwin Investment Management LLC increased its stake in shares of Shire PLC by 5.1% in the second quarter. Baldwin Investment Management LLC now owns 1,703 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 82 shares during the last quarter. Cohen Klingenstein LLC increased its stake in shares of Shire PLC by 2.1% in the second quarter. Cohen Klingenstein LLC now owns 5,566 shares of the biopharmaceutical company’s stock valued at $1,025,000 after buying an additional 117 shares during the last quarter. Finally, Capital Guardian Trust Co. increased its stake in shares of Shire PLC by 16.0% in the second quarter. Capital Guardian Trust Co. now owns 899 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 124 shares during the last quarter. Institutional investors and hedge funds own 24.26% of the company’s stock.

Related posts

Leave a Comment